Phase III Study of Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation.

Trial Profile

Phase III Study of Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Renal transplant rejection
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms RITUX-ERAH
  • Most Recent Events

    • 27 Feb 2017 Last checked against ClinicalTrials.gov record (NCT01350882).
    • 27 Feb 2017 Last checked against ClinicalTrials.gov record (NCT01350882).
    • 09 Nov 2015 Results published in the Transplantation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top